Stanley Druckenmiller’s Next 13F Likely Lands Monday. 3 Positions to Watch

Stanley Druckenmiller's Duquesne Family Office must file its Q3 13F by Monday, revealing holdings as of Sept. 30. Top positions in Q2 included Natera, Taiwan Semiconductor, and Insmed, with Natera being the largest at 19.9% of the portfolio. Analysts' average price targets for these stocks are 28% to 61% above current prices. Taiwan Semiconductor's sales have been record-high despite a stock price decline.

Original reporting
Published Nov 12, 2026, 2:53 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 3:13 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Stanley Druckenmiller’s Next 13F Likely Lands Monday. 3 Positions to Watch — source image
Decision brief

The 30-second read

$NTRANeutralLow
01

Why it matters

The filing may prompt short‑term attention to NTRA, TSM, and INSM, but no new corporate events are disclosed.

02

Market read

The piece is a routine pre‑filing preview; relevance is modest, mainly for traders tracking high‑profile fund activity.

03

What to watch

Potential upcoming earnings or product news from the three companies could drive price more than the 13F filing itself.

Relevance 4/10Novelty 2/10Timing: by Monday, Nov 16

Background

The article previews the upcoming 13F filing of Stanley Druckenmiller's Duquesne Family Office, summarizing its top three holdings as of June 30.

Company-level read

Ticker impact

$NTRANeutralMedium confidence
Context

Duquesne Family Office's 13F showed Natera as its largest holding as of June 30, and the fund added to the position in Q2.

Expected impact

potential upward pressure as investors watch for further accumulation

Evidence & confidence

The filing is due soon; any increase in the fund's stake could signal confidence and attract other buyers.

$TSMNeutralMedium confidence
Context

Duquesne increased its Taiwan Semiconductor (TSM) position by 19% in Q2, making it the second‑largest holding.

Expected impact

possible modest upside as the fund's stake is highlighted

Evidence & confidence

A disclosed increase by a high‑profile investor often draws attention, but no new operational news for TSM itself.

$INSMNeutralLow confidence
Context

Duquesne added to its Insmed (INSM) position in Q2, listed among the three biggest holdings.

Expected impact

minor upward pressure if the fund's stake is confirmed

Evidence & confidence

The filing confirms a prior increase; market reaction is likely muted.

Market effects

Highlights continued investor interest in biotech (NTRA, INSM) and semiconductor (TSM) sectors.

No immediate regional impact; the news is US‑focused.

Limited; only reflects a single high‑profile fund's holdings.

Counterpoint

The fund's additions may be already priced in; traders could wait for actual post‑filing moves.

Key entities

  • Stanley Druckenmiller

    Founder of Duquesne Family Office, noted investor.

  • Duquesne Family Office

    Manages a $4.35 billion portfolio; filing its Q3 13F.

Related articles

$GOOGHighAI 8/10

Forget SpaceX: This Potential Blockbuster IPO Has Attracted $26 Billion From AI Giants

Anthropic, an AI company, is preparing for an IPO with a potential market cap of $1.4 trillion, down from earlier estimates. It has secured $26 billion in investments from major AI players like Alphabet, Nvidia, and Microsoft. The company reported $33.2 billion in revenue for the nine months ended Sept. 30, but remains unprofitable. The IPO is expected to take place next week.

$NTRAMed

Natera CFO Defends CEO Switch, Calls $6 Billion Revenue Target a “Way Station”

Natera CFO David Brophy defended the CEO transition and outlined long-term revenue targets. He estimated a $20B-$40B market opportunity for Signatera, with $1B revenue expected this year. Brophy also discussed competition, pricing, and market expansion into colorectal cancer screening and early detection tests. Natera (NASDAQ:NTRA) develops genetic testing and molecular diagnostics for various health applications.